Literature DB >> 13679596

Identification of equine herpesvirus-1 antigens recognized by cytotoxic T lymphocytes.

Gisela Soboll1, J Millar Whalley2, Mathew T Koen2, George P Allen3, Darrilyn G Fraser4, Michael D Macklin5, William F Swain5, D Paul Lunn1.   

Abstract

Equine herpesvirus-1 (EHV-1) causes serious disease in horses throughout the world, despite the frequent use of vaccines. CTLs are thought to be critical for protection from primary and reactivating latent EHV-1 infections. However, the antigen-specificity of EHV-1-specific CTLs is unknown. The aim of this study was to identify EHV-1 genes that encode proteins containing CTL epitopes and to determine their MHC I (or ELA-A in the horse) restriction. Equine dendritic cells, transfected with a series of EHV-1 genes, were used to stimulate autologous CTL precursor populations derived from previously infected horses. Cytotoxicity was subsequently measured against EHV-1-infected PWM lymphoblast targets. Dendritic cells were infected with EHV-1 (positive control) or transfected with plasmids encoding the gB, gC, gD, gE, gH, gI, gL, immediate-early (IE) or early protein of EHV-1 using the PowderJect XR-1 research device. Dendritic cells transfected with the IE gene induced CTL responses in four of six ponies. All four of these ponies shared a common ELA-A3.1 haplotype. Dendritic cells transfected with gC, gD, gI and gL glycoproteins induced CTLs in individual ponies. The cytotoxic activity was ELA-A-restricted, as heterologous targets from ELA-A mismatched ponies were not killed and an MHC I blocking antibody reduced EHV-1-specific killing. This is the first identification of an EHV-1 protein containing ELA-A-restricted CTL epitopes. This assay can now be used to study CTL specificity for EHV-1 proteins in horses with a broad range of ELA-A haplotypes, with the goal of developing a multi-epitope EHV-1 vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679596     DOI: 10.1099/vir.0.19268-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.

Authors:  Shiliang A Liu; Brent A Stanfield; Vladimir N Chouljenko; Shan Naidu; Ingeborg Langohr; Fabio Del Piero; Jacqueline Ferracone; Alma A Roy; Konstantin G Kousoulas
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

2.  The common equine class I molecule Eqca-1*00101 (ELA-A3.1) is characterized by narrow peptide binding and T cell epitope repertoires.

Authors:  Tobias Bergmann; Carrie Moore; John Sidney; Donald Miller; Rebecca Tallmadge; Rebecca M Harman; Carla Oseroff; Amanda Wriston; Jeffrey Shabanowitz; Donald F Hunt; Nikolaus Osterrieder; Bjoern Peters; Douglas F Antczak; Alessandro Sette
Journal:  Immunogenetics       Date:  2015-09-23       Impact factor: 2.846

3.  Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2.

Authors:  Robert H Mealey; Matt H Littke; Steven R Leib; William C Davis; Travis C McGuire
Journal:  Vet Immunol Immunopathol       Date:  2007-04-08       Impact factor: 2.046

4.  Identification and characterization of duck plague virus glycoprotein C gene and gene product.

Authors:  Bei Lian; Chao Xu; Anchun Cheng; Mingshu Wang; Dekang Zhu; Qihui Luo; Renyong Jia; Fengjun Bi; Zhengli Chen; Yi Zhou; Zexia Yang; Xiaoyue Chen
Journal:  Virol J       Date:  2010-11-27       Impact factor: 4.099

5.  Induction of immune responses in ducks with a DNA vaccine encoding duck plague virus glycoprotein C.

Authors:  Bei Lian; Anchun Cheng; Mingshu Wang; Dekang Zhu; Qihui Luo; Renyong Jia; Fei Liu; Xinfeng Han; Xiaoyue Chen
Journal:  Virol J       Date:  2011-05-10       Impact factor: 4.099

Review 6.  EHV-1: A Constant Threat to the Horse Industry.

Authors:  Fatai S Oladunni; David W Horohov; Thomas M Chambers
Journal:  Front Microbiol       Date:  2019-12-03       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.